ABBREVIATIONS AE = adverse event; aSAH = aneurysmal subarachnoid hemorrhage; AUC = area under the curve; CRP = C-reactive protein; GOS-E = Glasgow Outcome Scale-extended; IL = interleukin; IL-1Ra = IL-1 receptor antagonist; IMP = investigational medicinal product; IV = intravenous; ln = natural log; SAE = serious AE; SC = subcutaneous; WFNS = World Federation of Neurosurgical Societies. OBJECTIVE Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating cerebrovascular event with long-term morbidity and mortality. Patients who survive the initial bleeding are likely to suffer further early brain injury arising from a plethora of pathological processes. These may result in a worsening of outcome or death in approximately 25% of patients and may contribute to longer-term cognitive dysfunction in survivors. Inflammation, mediated by the cytokine interleukin-1 (IL-1), is an important contributor to cerebral ischemia after diverse forms of brain injury, including aSAH. Its effects are attenuated by its naturally occurring antagonist, IL-1 receptor antagonist (IL-1Ra [anakinra]). The authors hypothesized that administration of additional subcutaneous IL-1Ra would reduce inflammation and associated plasma markers associated with poor outcome following aSAH. METHODS This was a randomized, open-label, single-blinded study of 100 mg subcutaneous IL-1Ra, administered twice daily in patients with aSAH, starting within 3 days of ictus and continuing until 21 days postictus or discharge from the neurosurgical center, whichever was earlier. Blood samples were taken at admission (baseline) and at Days 3-8, 14, and 21 postictus for measurement of inflammatory markers. The primary outcome was difference in plasma IL-6 measured as area under the curve between Days 3 and 8, corrected for baseline value. Secondary outcome measures included similar area under the curve analyses for other inflammatory markers, plasma pharmacokinetics for IL-1Ra, and clinical outcome at 6 months. RESULTS Interleukin-1Ra significantly reduced levels of IL-6 and C-reactive protein (p < 0.001). Fibrinogen levels were also reduced in the active arm of the study (p < 0.002). Subcutaneous IL-1Ra was safe, well tolerated, and had a predictable plasma pharmacokinetic profile. Although the study was not powered to investigate clinical effect, scores of the Glasgow Outcome Scale-extended at 6 months were better in the active group; however, this outcome did not reach statistical significance. CONCLUSIONS Subcutaneous IL-1Ra is safe and well tolerated in aSAH. It is effective in reducing peripheral inflammation. These data support a Phase III study investigating the effect of IL-1Ra on outcome following aSAH.
A neurysmAl SAH (aSAH) is an acute cerebrovascular event characterized by the rupture of an aneurysm within the subarachnoid space. There is initial global and local cerebral ischemia that constitutes the first insult. Subsequent secondary brain injury is multifactorial in origin, with vasospasm, brain edema, and cerebral inflammation thought to be major contributors. It affects 30%-50% of survivors and results in a high morbidity and mortality. 8 In addition, the long-term effects of aSAH in terms of cognitive and higher mental function are increasingly recognized to cause a significant lifelong burden. 28 There is evidence that a significant inflammatory response is seen in patients following all acute cerebrovascular events, in particular aSAH. 24 Interleukin (IL)-1 is a proinflammatory cytokine that is an important mediator of inflammation-mediated neuronal damage. IL-1 and its downstream mediators (in particular IL-6) are not neurotoxic in the normal milieu, but become significantly deleterious in neuropathological states such as intracerebral bleeding. In preclinical studies, IL-1 has been demonstrated to alter blood-brain barrier permeability 5 and to induce glial-mediated neurotoxicity. 34 Neutralization of IL-1 using IL-1b antibodies reduces vasospasm in experimental aSAH
19 that leads to exacerbation of preexisting cerebral ischemia.
Clinical observational studies have demonstrated that high concentrations of IL-1 and IL-6 are associated with vasospasm following SAH. 18, 27, 30 Recent studies using microdialysis technology have demonstrated that IL-6 is associated with incidence of vasospasm as well as a poor functional outcome following aSAH. 16 In addition, there is emerging evidence that following hemorrhagic stroke, hemoglobin and its breakdown products act as damageassociated molecular patterns and elicit an IL-1-mediated sterile inflammatory response that is neurotoxic. 13 Interleukin-1 receptor antagonist (IL-1Ra) is the naturally occurring antagonist to IL-1. It has been proven to be neuroprotective in various models of cerebral ischemia, including ischemic stroke. 4 Anakinra, a recombinant form of IL-1Ra, is used clinically as a second-line drug for autoimmune diseases such as rheumatoid arthritis and is currently being investigated in > 40 clinical conditions. Its safety profile in acute neurodegenerative disease and aSAH in particular has been well established. 6, 11, 32 Peripherally administered anakinra has been demonstrated to cross the blood-CSF barrier and the blood-brain barrier after SAH and traumatic brain injury. 14, 17 The biological activity and pharmacodynamics of subcutaneous (SC) IL1Ra have been studied extensively. 3 We previously demonstrated that intravenous (IV) anakinra reduces plasma and CSF IL-6 concentrations in patients with aSAH. 32 Intravenous administration is not as practical or as cost-effective as SC delivery for long-term administration during the period of heightened risk from secondary brain injury. The aim of the present study was to investigate the effect of SC IL-1Ra on the peripheral inflammatory response following aSAH, as a proof of concept of its biological effect in this patient population. We tested the feasibility and tolerability of twice-daily SC administration of IL-1Ra and obtained early data on efficacy to inform the design of future Phase III studies.
Methods

Overall Study Design
The 
Eligibility and Screening
Participants were considered eligible for the study if they had radiologically confirmed aSAH and if consent could be obtained and drug administered within 72 hours of ictus. Patients were excluded if they were < 18 years old, had abnormal renal function (creatinine > 177 mmol/L), had a previously recorded allergy to Escherichia coli, had known or suspected infection in the preceding 2 weeks or at the time of the study, or had participated in a clinical trial of an investigational medicinal product (IMP) in the preceding 30 days. Pregnant or breastfeeding patients, as well as those with active malignancy, were excluded. Verbal and written information was provided by the research team and a reapproach was made for consent from the patient or their legal representative. For those patients who were not able to provide initial consent but who regained capacity during the course of the study, reconsent was sought and obtained.
Randomization and Masking
As soon as consent was obtained, a baseline assessment was performed on each participant and a blood sample of up to 20 ml was taken. Clinical assessment included standard measures of aSAH severity, including the Fisher grade 9 and World Federation of Neurosurgical Societies (WFNS) grade. 33 Randomization to treatment or no treatment (1:1) was stratified for Day 1, 2, or 3 postictus. A second randomization allocated patients into 1 of the 3 plasma-sampling time groups (07:00, 13:00, or 19:00 hours), stratified by their allocated intervention group. This block sampling technique was designed to allow us to obtain 3 samples per day to confirm the pharmacokinetics of our chosen regimen without the need for repeated venipuncture of individuals. The process was performed using an Internet-based third-party randomization service (www. sealedenvelope.com), and the investigators were unaware of the block size throughout the study period. The control and IMP arms of the study were not matched.
Intervention Procedures
For participants allocated to the IMP arm, SC anakinra was injected at the next administration time point (07:00 or 19:00 hours) ± 2 hours, and continued twice daily until a maximum of 21 days postictus or discharge from neurosurgical care. This dosing regimen was informed by a pharmacokinetic model and tolerability data obtained from Amgen, Inc. It reflected a compromise between a relatively steady plasma concentration, our mean target concentration, and an acceptable rate of injection-site reactions. All patients underwent attempts at blood sampling daily from Days 3 to 8, and then on Days 14 and 21 postictus for those who were still inpatients at the neuroscience center.
Optimization of sampling times was performed using PopDes, as published previously. 15 All adverse events (AEs) were classified in line with published MHRA definitions (http://www.hra.nhs.uk/documents/2015/06/ safety-progress-reports-procedural-table-ctimps.pdf) and were reported in all patients up to 30 days from cessation of therapy (per Good Clinical Practice) to the independent data monitoring and safety committee. Patients were monitored closely; those with evidence of neurological deterioration underwent angiography to exclude symptomatic vasospasm, per our routine clinical practice.
Sample Processing and Analysis
Blood samples were collected into tubes containing EDTA and centrifuged at 2000g at 4°C for 15 minutes. Plasma was frozen at -70°C. All samples were transported to Salford Royal Foundation Trust and batch analyzed.
Concentrations of IL-6, IL-8, and C-reactive protein (CRP) were measured using Luminex bead technology. Interleukin-1Ra was measured by enzyme-linked immunosorbent assay and fibrinogen was measured by functional assay. Laboratory staff were blinded to treatment allocation, except for the individual measuring IL-1Ra.
Statistical Analysis
The primary outcome measure was the area under the curve (AUC) for natural log (ln) (IL-6) from Days 3 to 8. Patients were included in the analysis if they provided ≥ 4 blood samples from a possible total of 6. Secondary outcomes were corresponding AUCs for other biomarkers, all biomarkers up to Day 21, and Glasgow Outcome Scale-extended (GOS-E) score at 6 months. Sample size calculation was based on effects observed for ln(IL-6) and ln(CRP) after 72 hours of IV infusion in patients with ischemic stroke in our previous trial. 7 Our target recruitment was 64 participants per group for 80% power to detect a standardized effect size of 0.5. Analyses were on an intention-to-treat basis.
To calculate AUC, missing data points for an individual were imputed by fitting a linear regression to observed values on the log scale. Analysis of covariance was used to estimate the group difference for inflammatory markers, adjusting for baseline values of the relevant marker. The GOS-E scores were compared using ordinal logistic regression after confirming the proportional odds assumption. All analyses were adjusted for the randomization strata. Concentrations of IL-1Ra were plotted against prediction intervals calculated using the population pharmacokinetic data a priori.
Results
Patient Recruitment and Feasibility
Four hundred seventy-three patients were screened, and 136 were recruited from the 3 centers between October 2011 and November 2014 (Fig. 1, Table 1 ). Thirteen participants (10%) withdrew or were withdrawn from blood sampling, including 3 who became severely ill and were not expected to survive; 3 who were withdrawn for medical reasons (elevated liver function tests and rash of unknown etiology); and 2 who withdrew because of injection-site reactions. Patients ranged in age from 23 to 77 years, with a median age of 52 years. More than 80% had Fisher Grade 3 or 4, and a similar proportion had WFNS Grade I or II.
Pharmacokinetic Profiles
The plasma pharmacokinetic profile of IL-1Ra in patients receiving anakinra was within our predicted intervals (Fig. 2) , although the observed mean concentrations were lower than the predicted mean. Twice-daily dosing achieved a steady concentration profile with minimal peak trough fluctuation. The maximum plasma concentration was 1.6 mg/ml, and the minimum concentration was above our target median inhibitory concentration of 100 ng/ml.
Laboratory Results of Inflammatory Markers
Circulating IL-1Ra concentrations confirmed that all participants had been treated as allocated. Concentrations of IL-6 were elevated in both groups at baseline, remaining high in untreated participants, but falling by Day 3 postictus in IL-1Ra-treated participants. The mean values in untreated patients began to decline at approximately 1 week and continued to decline in both groups up to 3 weeks (Fig. 3 upper) . The mean levels of CRP showed a similar pattern of decline in each group, but decline was delayed by a few days in the control group (Fig. 3 lower) . Fibrinogen levels remained stable in treated participants but increased over the 1st week in control participants (data not shown). Levels of IL-8 remained stable throughout the sampling period. There were statistically significant differences (p < 0.001) between allocated groups for AUC analyses of both IL-6 and CRP (Table 2) . Sensitivity analyses for method of imputation made no substantive difference to the conclusions. There was also a statistically significant difference in fibrinogen levels (p = 0.002) but no difference in IL-8 levels between the 2 groups.
Clinical Outcome
Three patients were lost to follow-up. Two of these patients returned overseas and could not be contacted. The third patient was uncontactable, but his clinical review notes reported "permanent neurological deficit, due to memory problems and lethargy." The GOS-E scores (a secondary outcome measure) were better in the active than in the control group, although this was not statistically significant (OR 0.92, 95% CI 0.50-1.7; p = 0.80 [ Table 3 ]).
Safety and AEs
The AEs and serious AEs (SAEs) are listed in Table 4 . None of the SAEs were attributable to the IMP. Ten of 62 patients (16%) in the IMP group experienced an injectionsite reaction. Forty-six infections were detected in our 2 cohorts. There were no differences between the groups, either in the incidence of overall infections (i.e., those classified as an AE or an SAE) (OR 0.88, 95% CI 0.43-1.8) or of those infections classified as an SAE (i.e., the more severe ones) (OR 1.5, 95% CI 0.62-3.7). The overall incidence of delayed cerebral ischemia (DCI) was 42 patients (31%), of whom 22 (35%) were in the treatment group and 20 (32%) were in the control group. Cerebral vasospasm was demonstrated angiographically in 14 patients (23%) and 16 patients (26%) in these groups, respectively.
Discussion
This Phase II study demonstrates that recombinant IL1Ra, by SC administration, suppresses the IL-1-mediated response following aSAH. Inflammation mediated by IL-1 is increasingly recognized as an important contributor to neurodegeneration after acute cerebrovascular events. Al-
FIG. 3. Upper:
ln(IL-6) for patients receiving anakinra and control subjects at different time points. Lower: ln(CRP) for patients receiving anakinra and control subjects at different time points. though levels of both IL-1 and IL-6 are barely detectable in the brain under normal conditions, they can become rapidly upregulated to reach high concentrations, particularly in aSAH. Production of IL-6 can be upregulated by a wide variety of stimuli, including IL-1, tumor necrosis factor alpha, and transforming growth factor beta. High concentrations of IL-6 in plasma, CSF, and brain extracellular fluid are associated with poor outcome following SAH.
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We demonstrated previously that IL-1 antagonism using IV anakinra is a safe and effective way to reduce IL-6 following cerebral ischemic stroke 7 and SAH. 32 In this study, we have proven that administration of SC IL-1Ra, starting within 72 hours and continued for a maximum period of 21 days postictus, is safe and significantly reduces plasma concentrations of IL-6 following aSAH. This effect was seen as early as Day 3 postictus and persisted until Day 8. Levels of CRP were also reduced in the active treatment group, but the reduction occurred more slowly than the reduction in IL-6. This would be in keeping with a rise in CRP, mediated partly by IL-6. C-reactive protein has been demonstrated to be an independent predictor of outcome for patients presenting with a good grade of SAH. 36 Our results are encouraging because, in contrast to other drug trials, 21 anakinra has significantly reduced CRP levels. We did not detect any significant change in IL-8 levels in our study. Data from our previous preclinical studies have suggested that one of the mechanisms by which inflammation is detrimental to cerebral ischemia is through IL-1-induced potentiation of neutrophil mobilization via CXC chemokine induction. 23 The IL-8 results in this study may have multiple implications. First, the mean IL-8 levels (13 pg/ml) were higher than those reported in a study of ischemic stroke (4.3 pg/ml), 22 which might imply that neutrophil chemotaxis plays a more prominent role in aSAH. Second, although IL-1 can potentially upregulate both IL-6 and IL-8, it induces IL-6 gene expression in a mechanism independent of IL-8 upregulation, a phenomenon previously reported. 29 Finally, IL-8 production may not be IL-1 dependent in aSAH. We have previously shown that antagonism of IL-1, using IL-1Ra, reduced neutrophil counts in patients with aSAH.
11 However, it is also possible that either the dose of anakinra used in the current study was not sufficiently high to suppress IL-8-mediated neutrophilia or that IL-1Ra blocks polymorphonuclear mobilization independent of IL-8.
Fibrinogen levels were reduced in the active treatment group. This would be in keeping with the action of IL1Ra in other inflammatory disease states, such as juvenile rheumatoid arthritis, where anakinra has an established therapeutic use and where fibrinogen levels correlate with disease activity.
12 Fibrinogen levels, in addition to CRP platelet activation, have been previously demonstrated to be associated with worse outcomes following aSAH.
10
Although we have no evidence that IL-1Ra improves outcome by reducing fibrinogen levels, it is nevertheless reassuring that in our study, anakinra reduces a number of inflammatory markers that have been associated with poor outcomes following aSAH.
We acknowledge limitations and shortcomings in our clinical trial. The characteristics of our study population reflected those of the disease population. Groups were similar with respect to clinical severity (WFNS and Fisher grades), the day postictus, and age. As expected, most patients were women and a high proportion were smokers. For pragmatic reasons, this was an open-label, single-blinded study, but the primary outcome was a laboratory analysis. All laboratory staff were blinded to treatment allocation, and IL-1Ra assays were performed after measurement and documentation of other cytokines. Our block sampling technique introduced additional variability within groups due to timing. However, this additional variability was balanced by design, and we observed clear differences despite this.
Another potential shortcoming of the study is that most of the patients assigned to the IMP group were administered anakinra on Day 2 (77%) or Day 3 (7%) following ictus. This is not reflective of its potential clinical use, where anakinra could be given immediately after diagnosis of SAH, as is routine practice with nimodipine in the United Kingdom. The main reason for the delay in our study was to ensure that patients, or their representatives, had adequate time to consider the information they were provided prior to giving their consent.
There is increasing preclinical 5 and clinical evidence 25 suggesting that IL-1 is associated with increasing blood- brain barrier permeability and worsening clinical outcome. Therefore, IL-1Ra could have potentially significant benefit if given earlier following aSAH. Similarly, the beneficial effect of anakinra on limiting neurotoxicity and hememediated inflammation may be significantly enhanced with earlier administration. For this reason, we intend to adopt ultra-early administration of the drug, i.e., as soon as aSAH is diagnosed, in our planned Phase III study. Anakinra is currently licensed for use as a first-line therapy for neonatal-onset multisystem inflammatory disease and as a second-line treatment for adult rheumatoid arthritis (www.kineretrx.com). In these patients, for whom it is given as a long-term treatment, anakinra has an excellent safety and tolerability profile. 31 Our group has used short-term (4-72 hours) anakinra treatment in patients with stroke and SAH, using both IV and SC formulations, with a similar favorable safety profile. 6, 7, 11, 32 To our knowledge, this is the first reported study in which SC anakinra was administered for longer periods (up to 21 days) in this population cohort and for which there is a plasma inflammatory profile extending beyond 72 hours. Moreover, to ensure minimal peak-trough fluctuations, our dosing regimen was twice rather than once daily.
Most participants (81%) receiving anakinra had a relatively good WFNS grade (WFNS Grades I-III) with a good level of consciousness, and they tolerated the drug well. No safety concerns were experienced throughout the duration of the study. Despite the fact that people with aSAH have a high incidence of infection (particularly hospital-acquired pneumonia and ventriculitis), there was no statistically significant difference in the proportion of patients reported to have infection (21 infections in the actively treated group and 25 in the control group). More of the infections reported as SAEs were in the actively treated group, but this did not achieve statistical significance. There was no trend to any particular infection type.
There have been many Phase III clinical studies in SAH, but only the British Aneurysm Nimodipine Trial has demonstrated efficacy. 1 Oral nimodipine demonstrated a significant reduction in cerebral infarction and poor outcome at 3 months by reducing the number of deaths and disabilities in patients with episodes of DCI. Although the causes for DCI are multifold, studies suggest that nimodipine acts primarily by reversing macroscopic cerebral artery vasospasm. 2 Phase III studies further targeting arterial spasm (in part or wholly), including magnesium and clazosentan, have failed to show additional benefit on outcome. Given the effect size of nimodipine, any further improvement in outcome following SAH is more likely to be obtained by targeting causes of DCI and neurodegeneration other than arterial spasm.
The theoretical multimodal mechanism of action of statins (including the potential effect of statins on inflammation) was promising; however, both low-and high-dose simvastatin failed to show an adequate suppression of inflammation (CRP) and improved outcome. 21 The causes of failure for these Phase III studies are varied and include insufficient pharmacokinetic information, lack of proof of action in the target disease population, alteration of beneficial physiological responses, as well as others. The enthusiasm of neurosurgical centers worldwide to continue to recruit patients to Phase III studies in aSAH reflects the appreciation that research into improving outcomes in this patient group remains a significant unmet clinical demand.
Current strategies being considered besides IL-1 antagonism include reducing oxidative stress 26 and endothelin expression. 35 To our knowledge, this study is the first to show a significant reduction in plasma inflammation following aSAH, and therefore places IL-1 antagonism as a promising strategy for future Phase III studies. Our study was not powered to compare clinical outcomes between the active and control groups; however, it provides crucial pilot data for a Phase III study, for which funding is currently being sought.
Conclusions
We have studied the effects of IL-1 and its antagonist at the cellular level in experimental models of cerebrovascular disease. We have demonstrated proof of biological efficacy of IL-1 antagonism at both the preclinical and clinical levels using different administration routes. In conjunction with previously published data, this study provides robust pharmacokinetic data for SC anakinra with respect to achieving therapeutic plasma concentrations in patients with aSAH. We now have evidence that 1) IL-1 is detrimental in cerebral ischemia; 2) IL-6 and CRP are associated with poor outcome after aSAH; and 3) SC anakinra, when given within a reasonable time window after SAH, is associated with a reduction in IL-6 plasma levels. With these data, anakinra is a very promising candidate for neuroprotection after SAH and is uniquely positioned for evaluation in a Phase III study.
